G
Gain Therapeutics
Biotech & Life Sciences · Lugano, Switzerland · Founded 2017 · IPO 2021
Preclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary… MoreLess
Gain Therapeutics is a biotechnology company focused on developing innovative small molecule therapeutics for disorders with high unmet medical needs. Utilizing a combination of physics-based methods and artificial intelligence, Gain Therapeutics creates next-generation allosteric small molecules that can modulate proteins to restore or disrupt their function. These molecules can inhibit, activate, stabilize, destabilize, or degrade proteins based on the specific disease pathology. The company primarily serves the healthcare and pharmaceutical sectors, targeting conditions that currently lack effective treatments. Gain Therapeutics operates in the global biotechnology market and follows a business-to-business (B2B) model, partnering with other pharmaceutical companies for clinical development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.
Keywords: biotechnology, small molecules, allosteric modulation, protein regulation, AI-driven drug discovery, high unmet need, healthcare, pharmaceuticals, B2B, licensing agreements.
Company overview
Gain Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lugano, Switzerland
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 61.8
Valuation & funding
Gain Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2025 | $7M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jun 2024 | $11M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Nov 2023 | $9.4M | — | Undisclosed | ↗ |
| GRANT✓Other financing | May 2023 | $2.8M | — | Innosuisse | ↗ |
| IPO✓Exit | Mar 2021 | $40M | $40M | Undisclosed | — |
| SERIES B✓Equity / VC | Jul 2020 | Undisclosed | ↗ | ||
| GRANT✓Other financing | Oct 2019 | Undisclosed | — | ||
| SERIES A✓Equity / VC | Feb 2019 | TiVentures · 3B Future Health Fund | — | ||
| CORPORATE SPINOUT✓Other financing | Jul 2017 | Minoryx Therapeutics | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Gain Therapeutics website traffic
Latest recorded traffic for Gain Therapeutics is 21K monthly website visits, up 75% over the last three months. Gain Therapeutics's team declined 19.4% over the past year.
Comparisons
Gain Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Gain Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on Gain Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Gain Therapeutics has talent and traffic
team presence
In the news
Latest news about Gain Therapeutics
Recent press, funding announcements, and product moves mentioning Gain Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Gain Therapeutics
An AI-synthesized read of the highest-engagement posts about Gain Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gain Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.